How can cfONCO- Lung help you？
Oxford offers you cfONCO- Lung, non-invasive test through next generation screening technology, to test the mutation of lung cancer (including the latest SNP highly relate with the lung cancer.) It is also provided with targeted drugs recommendation approved by FDA, assisted treatment alternatives, post-treatment monitoring and evaluation of targeted drugs, early detection of drugs resistance in cancer targeted treatment. 
Highlight: - Non-Invasive- provide an alternative to sbustitue for lung cancer tissue sample and senior patients as well. Only a tube of plasma sample is valid for the test. The volume of cfDNA test is different for each patient, and the least volume is only 1 ng.
- Low limit of detection- Enable variant detection down to 0.1%, with 90% sensitivity and >98% specificity for SNV hoptspots and indels.
- High value content- more than 165 hotspots, including EGFR T790M、L858R etc.
- Enable tumor heterogeneity- A breakthrough of heterogeous cancer cells which might cause drugs resisistance. ctDNA test helps to monitor somatic mutation from time to time.
cfONCO- Lung
Content
ALK, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, and TP53
> 165 hotspots
SNVs and INDELs including:
EGFR: T790M, C797S, L858R, Exon 19 del、KRAS: G12X, G13X, Q61X、BRAF: V600E、ALK: Exon 21-25、PIK3CA: E545K, H1047R, E542K
> 165 hotspots
SNVs and INDELs including:
EGFR: T790M, C797S, L858R, Exon 19 del、KRAS: G12X, G13X, Q61X、BRAF: V600E、ALK: Exon 21-25、PIK3CA: E545K, H1047R, E542K
Technology
Next Generation Sequencing
Participants
Primary Lung cancer
Substitute for lung cancer tissue sample
Senior patients
Substitute for lung cancer tissue sample
Senior patients
Significance
ctDNA test helps to monitor somatic mutation from time to time.
Concept of Analysis
The results of screening will compare with Human Genome version 19 (hg19). The drug database provides FDA-approved cancer target drugs.
* please call or email if you need more information
